(Q35884830)

10 August 2017

0 references

Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy (English)

1 reference

10 August 2017

0 references

1 reference

1 reference

Tauqeer Ahmed

1

1 reference

10 August 2017

Ritwik Pandey

series ordinal

2

1 reference

10 August 2017

Bhavini Shah

series ordinal

3

1 reference

10 August 2017

Jason Black

series ordinal

4

1 reference

10 August 2017

14 July 2015

1 reference

10 August 2017

1 reference

10 August 2017

2015

1 reference

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Nivolumab plus ipilimumab in advanced melanoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Management of immune-related adverse events and kinetics of response with ipilimumab

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Final version of 2009 AJCC melanoma staging and classification

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4513455

14 November 2018

Identifiers

DOI

10.1136/BCR-2014-208102

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

26174726

1 reference